UC HEALTH LINE: In Treating Stroke, Time Is of the Essence
UCs neurology department has been involved in developing stroke treatment since the early studies of tissue plasminogen activator (t-PA), the only Food and Drug Administration-approved treatment for acute ischemic stroke. Intravenous t-PA has been found to be effective if administered within three hours of stroke onset, and more effective if given sooner. But how the timing of starting this medicine in a stroke patient relates to the timing of when the blood vessel is actually opened has not been known.
In recent years, physicians have started investigating methods for directly dissolving or removing blood clots using a catheter in brain vessels, called the intra-arterial approach. Evidence has suggested that this method may be more effective than intravenous t-PA, but no data was previously available on how much time matters in this setting.
Khatri, an assistant professor of neurology and member of the Neuroscience Institute at UC and
She and a team of researchers analyzed data from a multicenter international stroke trial coordinated by UC, which was testing the safety of low-dose intravenous t-PA followed by intra-arterial treatments. They analyzed how the timing of when blood flow was restored affected the chance of a good recovery.
Khatris team found that the chance of a good outcome after opening a blood vessel became progressively less over time, and by about seven hours after stroke onset, the chance for a good outcome approached that of someone who had received no treatment at all.
This is the first clear evidence that time is a strong determinant of outcome, even if a blood vessel is successfully opened, says Khatri. It reinforces the notion that stroke treatments and stroke health care delivery must emphasize speed.
Results of their study were presented today at the annual International Stroke Conference in
The Siekert Award is presented annually in honor of Robert Siekert, founding chairman of the American Heart Associations International Conference on Stroke and Cerebral Circulation. The award encourages new investigators to undertake or continue stroke-related research.
She is the second UC investigator to receive this award. Dan Woo, MD, associate professor of neurology, received the honor in 2004.
Coauthors for Khatris study include Todd Abruzzo, MD, radiology, Joseph Broderick, MD, neurology, and Thomas Tomsick, MD, radiology, all from UC, and Sharon Yeatts, PhD, from the Medical University of South Carolina.
The Neuroscience Institute is a collaborative effort of nine academic departments at the UC College of Medicine, the
-30-
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.